Financial Performance - The company's revenue for Q1 2023 was CNY 124,226,061.67, representing a 9.52% increase compared to CNY 113,428,452.99 in the same period last year[5] - Net profit attributable to shareholders was CNY 32,088,662.63, up 16.91% from CNY 27,447,995.23 year-on-year[5] - Total operating revenue for Q1 2023 reached CNY 124,226,061.67, an increase of 9.3% compared to CNY 113,428,452.99 in Q1 2022[19] - Net profit for Q1 2023 was CNY 32,088,662.63, representing a 16.0% increase from CNY 27,447,995.23 in the same period last year[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.55, compared to CNY 0.47 in Q1 2022, indicating a growth of 17.0%[21] Cash Flow - The net cash flow from operating activities increased by 8.66% to CNY 14,153,258.65, compared to CNY 13,025,272.93 in Q1 2022[5] - Cash inflow from operating activities totaled CNY 100,238,318.64, significantly higher than CNY 76,634,292.36 in Q1 2022, marking an increase of 30.8%[23] - The net cash flow from operating activities for Q1 2023 was CNY 14,153,258.65, an increase from CNY 13,025,272.93 in Q1 2022[24] - Cash inflow from financing activities reached CNY 783,366,482.86, with a significant increase due to CNY 782,943,530.00 from investment absorption[24] - The net cash flow from financing activities was CNY 782,755,517.13, a substantial improvement from a net outflow of CNY 289,018.87 in Q1 2022[24] - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 932,397,769.05, up from CNY 70,331,727.17 at the end of Q1 2022[24] - The net increase in cash and cash equivalents for the quarter was CNY 783,423,545.31, compared to CNY 4,982,869.43 in the same period last year[24] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 1,446,370,989.83, a significant increase of 121.91% from CNY 651,789,219.99 at the end of the previous year[5] - Current assets increased to CNY 1,083,076,504.11 from CNY 282,267,007.37, reflecting a substantial rise in liquidity[17] - The total liabilities decreased slightly to CNY 129,206,942.92 from CNY 132,061,203.18, a reduction of 2.1%[20] - The total equity attributable to shareholders rose by 153.43% to CNY 1,317,164,046.91 from CNY 519,728,016.81 at the end of the previous year[5] - The company is focusing on enhancing its financial position and operational efficiency as indicated by the changes in asset and liability structures[16] Expenses - Total operating costs amounted to CNY 89,130,543.28, up from CNY 82,896,009.48, reflecting a year-over-year increase of 7.5%[19] - Research and development expenses increased by 76.56% to CNY 8,110,172.85, compared to CNY 4,593,419.18 in Q1 2022, indicating a focus on innovation[10] - The company experienced a 197.31% increase in sales expenses, totaling CNY 14,413,879.74, primarily due to increased promotional activities[10] - Sales expenses increased to CNY 14,413,879.74 from CNY 4,848,066.82, a rise of 197.5% year-over-year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,244, reflecting a growing investor interest[12] - The total equity attributable to shareholders of the parent company increased to CNY 1,317,164,046.91 from CNY 519,728,016.81, a growth of 153.5%[20] Other Information - The first quarter report was not audited[25]
科源制药(301281) - 2023 Q1 - 季度财报